John Lin, MD, was a fellow in the Division of Hematology and Oncology at the University of Pennsylvania. His current research interests are in evaluating the value of novel and high-cost oncology therapies as well as assessing the impact of payment policies on patients who have cancer. His research has appeared in journals such as The Lancet, the Journal of Clinical Oncology, and The Lancet Global Health.

Dr. Lin holds an AB in Economics and Healthcare Policy from Harvard University and an MD from the Baylor College of Medicine. He completed his Internal Medicine residency at the University of California San Francisco in 2017 and a VA fellowship in Health Services Research and Development at the Center for Health Policy and the Center for Primary Care and Outcomes Research at Stanford University in 2019.